HAYA Therapeutics Announces Scientific Advisory Board

  • Leaders in the fields of RNA and cardiovascular disease join HAYA to advance its pipeline of therapeutics targeting long non-coding RNAs

LAUSANNE, Switzerland — HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), today announced the formation and members of its Scientific Advisory Board (SAB). The group of world-renowned leaders and pioneers are recognized for their work in lncRNA biochemistry, cardiovascular disease, antisense technology and fibrotic diseases, and will work closely with HAYA to support the company’s mission to bring novel anti-fibrotic therapies to the clinic.

READ MORE